| Literature DB >> 31934366 |
Carina Gottwald1, Norbert Georg Schwarz2, Hagen Frickmann3,4.
Abstract
INTRODUCTION: The study was performed to estimate the prevalence and determinants of occurrence of sexually transmitted infections (STIs) in paratroopers and navy soldiers by anonymously analyzing medical records from the medical departments of two large German barracks in order to assess the need for medical STI prevention.Entities:
Keywords: STI; management; navy soldier; paratrooper; risk assessment; sexually transmitted infection; soldier
Year: 2019 PMID: 31934366 PMCID: PMC6945994 DOI: 10.1556/1886.2019.00023
Source DB: PubMed Journal: Eur J Microbiol Immunol (Bp) ISSN: 2062-509X
Characterization of the assessed populations of paratroopers and navy soldiers. Not all assessed parameters were available for all patients
| Paratroopers ( | Navy soldiers | |
|---|---|---|
| Females in % ( | 5% (4/80) | 1.3% (1/80) |
| Median age in years | 28 | 29 |
| Mean age in years (± standard deviation SD) | 27.5 (±5.7) | 32.0 (±10.2) |
| Median age of STI patients in years | 26.5 | 26 |
| Mean age of STI patients in years (± standard deviation SD) | 26 (±3.7) | 26.8 (±4.9) |
| Officers in % | 2.5% (2/80) | 17.5% (14/80) |
| Senior non-commissioned officers in % | 15% (12/80) | 22.5% (18/80) |
| Junior non-commissioned officers in % | 22.5% (18/80) | 31.3% (25/80) |
| Privates in % | 60% (48/80) | 28.8% (23/80) |
| Previous deployments in % | 42.5% (34/80) | 48.8% (39/80) |
| Without primary partnership in % | 39.1% (9/23) | 42.9% (18/42) |
| With primary partnership, not married in % | 47.8% (11/23) | 33.3% (14/42) |
| With primary partnership, married in % | 13.4% (3/23) | 23.8% (10/42) |
| Documented sexual risk behaviors in % | Not documented | 25% (1/4) |
| Documented sexual contacts with multiple partners in % | Not documented | 25% (1/4) |
| Unprotected sexual intercourse in % | 90.9% (10/11) | 100% (7/7) |
| STI in medical history in % | 100% (3/3) | 66.7% (4/6) |
| Sexual intercourse with sex workers in % | Not documented | 33.3% (1/3) |
| Anal sexual intercourse in % | Not documented | 0% (0/3) |
| Vaginal sexual intercourse in % | Not documented | 100% (4/4) |
| Oral sexual intercourse in % | Not documented | 0% (0/2) |
| Men-having-sex-with-men (MSM) in % (n) | Not documented | 0% (4/4) |
| Sexual intercourse with different sex (heterosexual) in % | 100% (1/1) | 100% (4/4) |
| Bisexual contacts in % | Not documented | 0% (0/4) |
| Number of sexual partners within the previous 3 months (number of documentations) | Not documented | 0(4) |
| Total number of sexual partners | Not documented | 0 (1 |
Suspected and confirmed STI in the assessed paratroopers and navy soldiers
| Paratroopers | Navy soldiers | |
|---|---|---|
| Proportion of suspected STI in % (n, suspected diagnoses) | 17.5% (14/80, 1x chlamydial urethritis, 1 | 20% (16/80, 5 |
| Cases with proven STI in % (n) | 13.9% (11/79) | 11.3% (9/80) |
| Documented STI acquisition on deployment | 0% (0/6) | 10% (1/10) |
| Disease recurrence | 66.7% (2/3) | 100% (6/6) |
| Number of documented disease recurrences (x number of documentations) | 3(1 | 3(1 |
| Localizations of STI associated lesions | 5 | 2 |
| genital + hands (scabies) | ||
| Diagnostic confirmation in % | 64.3% (9/14) | 64.3% (9/14) |
| Highly suggestive clinical symptoms in % | 92.3% (13/14) | 73.3% (11/15) |
| Laboratory-based confirmation in % | 61.5% (8/13) | 61.5% (8/13) |
| Documented therapy of sexual partners | 80% (4/5) | 83.3% (10/12 with 1 case with only non-consistent partner therapy) |
| Duration between symptoms and medical | 83.3% (5/6) | 36.4% (4/11) |
| assessment <1 month in % | ||
| Duration between symptoms and medical | 0% (0/6) | 27.3% (3/11) |
| assessment <3 month in % | ||
| Duration between symptoms and medical | 16.7% (1/6) | 18.2% (2/11) |
| assessment <12 month in % | ||
| Pharmacological therapy performed in % | 100% (12/12) | 100% (14/14) |
| Pharmacological therapy performed in line with national guidelines | 91.7% (11/12) | 85.7% (12/14) |
| Diagnostic therapy control performed in % | 66.7% (8/12) | 42.9% (6/14) |
| Detection of | Not documented | 66.7% (2/3) |
| Detection of | 50% (3/6) | 66.7% (2/3) |
| Detection of | 0% (0/6) | 0% (0/5) |
| Detection of | 0% (0/3) | 50% (2/4) |
| Serological proof of syphilis in the case of screening in % | 0% (0/5) | 0% (0/4) |
| Detection of human immunodefiency virus (HIV) in the case of screening in % | 0% (0/8) | 0% (0/8) |
| Detection of | 0% (0/2) | 0% (0/1) |
| Detection of | 0% (0/2) | 0% (0/1) |
| Detection of | Not documented | 0% (0/1) |
| Detection of | Not documented | Not documented |
| Detection of genital herpes simplex type 1 virus infections in the case of screening in % | 0% (0/2) | 50% (1/2) |
| Detection of genital herpes simplex type 2 virus infections in the case of screening in % | 0% (0/2) | 0% (0/1) |
| Detection of human papillomavirus in the case of screening in % | 80% (4/5) | 85.7% (6/7) |
| Detection of hepatitis B virus in the case of screening in % | 0% (0/73) | 0% (0/49) |
| Detection of hepatitis C virus in the case of screening in % | 0% (0/12) | 0% (0/9) |
| Detection of | Not documented | 100% (1/1) |
| Detection of | 100% (3/3) | 50% (1/2) |
| Detection of | Not documented | Not documented |
| Detection of | Not documented | 100% (1/1) |